Table1_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.PDF by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image1_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image1_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image2_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image2_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image2_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image1_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Image3_RETRACTED: Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts.JPEG by Yingzi He (12259307)

“…Additionally, BrdU immunostaining and western blot analysis showed that TSA or VPA treatment caused a significant decrease in the percentage of S-phase cells and induced p21^Cip1 and p27^Kip1 expression, both of which are likely to explain the decrease in the amount of newly regenerated hair cells in treated embryos. …”

Structural clashes in TP53 mutants: (A) G266E mutation causes steric clashes with PHE109 and LEU257, destabilizing the structure. by Ashraf Attia Mahmoud (21262201)

S1 Data - by Jessica C. M. Hui (20370522)

“…Compared to the SD, the HFD and SDG models exhibited significantly increased and decreased contraction velocities and could be used as models of diarrhoea and constipation in DM, respectively, while the ED model showed comparatively little change in motility. …”

Uvrag in Tregs is dispensable for establishment of immune tolerance and eTreg accumulation. by Erienne G. Norton (9612079)

Specifications of prototypes of RSSCA system. by Ngoc-Hai Vu (22290844)

“…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Changes in bioimpedance by sex. by Domingos L. S. Rios (20496173)

“…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”

Clinical and epidemiological characteristics. by Domingos L. S. Rios (20496173)

“…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”

Changes in bioimpedance by age. by Domingos L. S. Rios (20496173)

“…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”

S1 Data - by Domingos L. S. Rios (20496173)

“…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”

Number of phylogroups occurring in individuals. by Rasel Barua (768634)

“…The most abundant phylogroup in all gut locations was B2 followed by A, B1, and D. Strain richness overall and across gut locations was decreased if an individual’s dominant strain belonged to phylogroup B2. …”